Drug Type Small molecule drug |
Synonyms NAV2729 |
Target |
Action inhibitors |
Mechanism ARF6 inhibitors(ADP ribosylation factor 6 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Preclinical | Austria | 05 Dec 2022 | |
Triple Negative Breast Cancer | Preclinical | United States | 01 Dec 2022 | |
Inflammation | Preclinical | - | 30 Nov 2022 | |
COVID-19 | Preclinical | - | 21 Nov 2022 | |
Uveal Melanoma | Preclinical | United States | 02 Jun 2016 | |
Uveal Melanoma | Preclinical | United States | 02 Jun 2016 | |
Uveal Melanoma | Preclinical | United States | 02 Jun 2016 | |
Uveal Melanoma | Preclinical | United States | 02 Jun 2016 |